Glenmark Pharmaceuticals Expands Innovation Footprint with Ryaltris U.S. Launch
Published: 08 Apr 2026
Author: Deepa Pandey
Glenmark Pharmaceuticals Inc. (Glenmark) announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg per spray in the U.S., effective April 1, 2026. This marks a significant milestone in Glenmark's continued expansion in the region with a sustainable approach to building a strong and direct commercial U.S.-based presence.
RYALTRIS was launched in the U.S. in 2022 and is approved by the U.S. Food and Drug Administration (FDA) for treating symptoms associated with Seasonal Allergic Rhinitis (SAR) in both adults and pediatric patients aged 12 years and older. This product is a fixed-dose combination nasal spray that combines olopatadine hydrochloride, an antihistamine, and mometasone furoate (a corticosteroid) in a single formulation. It is supplied as a 240-metered spray nasal suspension.
Seasonal Allergic Rhinitis affects millions of people in the U.S., and addressing symptom control and treatment adherence remains crucial. By combining two established therapies into one formulation, RYALTRIS offers a convenient treatment option that aligns with the evolving preferences of both healthcare providers and patients.
Glenmark will directly take the lead on brand strategy, market access, and customer engagement for RYALTRIS in the U.S. This approach allows for more focused execution, closer alignment with healthcare providers, and a greater ability to respond to market needs.
Marc Kikuchi, President & Business Head, North America, commented that, "The commercialization by Glenmark for RYALTRIS in the United States is a crucial step forward for the growth of our company. It allows us to get greater operational direction in how we engage the market and support healthcare providers and patients nationwide. The announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the U.S. and build a more direct, sustainable commercial presence over time."
According to Precedence Research, the nasal sprays market size was USD 6.50 billion in 2025 and is projected to increase from USD 6.99 billion in 2026 to approximately USD 13.52 billion by 2035, expanding at a CAGR of 7.60% from 2026 to 2035, driven by rising air pollution levels, high demand for corticosteroid sprays, rising availability of Over-the-Counter (OTC) sprays, and increasing product innovation.
RYALTRIS is already approved in several major markets, including the U.S., the European Union, the UK, Australia, South Korea, Russia, and China. In FY26, RYALTRIS was launched in 11 additional markets, expanding its presence to 55 countries across the globe.